Latest news Dr Kosh Agarwal discusses results of the REEF-2 study at the International LIver Congress. Photo © Steve Forrest & Andrew McConnell / EASL.New & experimental hepatitis B treatmentsExperimental hepatitis B combination suppresses key marker but fails to achieve functional cure. Life after the curePeople cured of hepatitis C remain at higher risk of death due to liver- and drug-related causes. Liver transplantsShort-course treatment prevents hepatitis C after organ transplant. infohep news New Bulevirtide leads to sustained improvement for hepatitis D patients Liz Highleyman / 13 hours ago The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ... New and experimental treatments for hepatitis B Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure Keith Alcorn / 27 June 2022 People with hepatitis B who received a combination of experimental drugs as well as their standard treatment for 48 weeks were significantly less likely to have high levels of hepatitis B surface ... View all infohep news Editors' picks from other sources WHO publishes updated guidance on hepatitis C infection – with new recommendations on treatment of adolescents and children, simplified service delivery and diagnostics World Health Organization / 24 June 2022 Acute hepatitis outbreak swells to nearly 900 cases; global data shows ‘mixed picture’ Healio / 24 June 2022 GPs could initiate treatment for chronic hepatitis C, say researchers Pulse / 03 June 2022 View all news from other sources Noticeboard ILC 2016 webinar: watch again More noticeboard posts Email updates Sign up for our monthly bulletins Sign up today Other pages in this section Latest news All the news Conference news Noticeboard Email bulletins News feeds